Atossa
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
107 Spring St, Seattle, Washington, 9810...Phone Number
(206) 588-0256Website
www.atossatherapeutics.comRevenue
$5.1 MillionStock Symbol
ATOSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Atossa
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.Explore more
Atossa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atossa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Atossa launches new products
Website visits: Recent activity has been detected on your website
Atossa, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Atossa recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Atossa is spiking on competitors!
Click to see if Atossa had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Atossa has new funding data
Check if Atossa has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Atossa
Recommended Actions
Find VP level buyers at Atossa
Find more new buyers
Compare Similar Companies to Atossa
Compare insights from companies similar to Atossa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atossa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atossa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atossa.
Atossa financials insights
Gather financial insights about Atossa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Stock Offering
$4M
2013
Stock Offering
$30M
2015
Stock Offering
$25M
2016
Stock Offering
$10M
2018
Private Equity
$13.4M
2019
Stock Offering
$10M
Atossa Tech Stack
A closer look at the technologies used by Atossa
See more technologies
Most Recent Scoops
Project
Atossa is conducting the RECAST-DCIS trial (Re-evaluating Conditions for Active Surveillance as Suitable Therapy for stage zero lesions) at UCSF, testing three endocrine therapies including endoxifen as an alternative to surgery and radiation, with 40 to 50 patients currently enrolled and the majority of participants choosing to remain on treatment beyond the initial six-month assessment period.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Atossa is collaborating with the FDA's Oncology Center of Excellence to establish early clinical endpoints including pathologic complete response (PCR) and residual cancer burden scale cut points as valid measures for trial design, with proposed thresholds of approximately 1 to 2 on the residual cancer burden scale for hormone-positive cancers and 1.1 for HER2-positive cancers.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Atossa is pursuing a neoadjuvant strategy for stage 2 and 3 early-stage breast cancer using endoxifen, targeting a Ki-67 cell turnover rate below 10% as an early endpoint consistent with findings from the POETIC study within the ATAC trial as a potential pathway to regulatory approval of endoxifen as a treatment option.
Medical Research, Pharmaceuticals
Project
Atossa has enrolled approximately 3,800 patients across I-SPY 2 and I-SPY 2.2, out of nearly 6,000 screened, and in July 2022 transitioned the trial to an adaptive design format that individualizes treatment based on each patient's data.
Project
Clinical Operations
Atossa News & Media
Atossa Therapeutics Secures $4.5M in Direct Offering, Eyes $16.5M in Warrants
Atossa Therapeutics closed a registered direct offering of 1,363,637 shares of common stock and accompanying warrants, raising $4.5 million in gross proceeds.Atossa Therapeutics Announces Closing of Registered Direct Offer - GuruFocus
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR NewswireAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale
Atossa Therapeutics sells 1.36M shares with Series A and B warrants at $3.30, raising $4.1M net and potentially $12M more on warrant exercises for clinical development funding.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atossa
Sign Up For FreeTo access detailed company insights
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.... Read More
